Recursion Pharmaceuticals Inc (RXRX)

7.66 +0.42 (+5.80%) USD  |  NASDAQ  |  Dec 26, 16:00
7.64 -0.02 (-0.26%) Pre-Market: 08:38
More

Recursion Pharmaceuticals Research and Development Expense (Quarterly): 74.60M for Sept. 30, 2024

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for RXRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Revance Therapeutics Inc 11.38M
Intuitive Surgical Inc 286.00M
NovaBay Pharmaceuticals Inc 0.004M
Palatin Technologies Inc 5.744M
iBio Inc 1.305M